Kaplan Fox Reminds Investors of ARS Pharmaceuticals Inc. (SPRY) to a Securities Class Action Deadline - Contact the Firm Before October 5, 2026

Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against ARS Pharmaceuticals Inc. ("ARS" or the "Company") (NASDAQ: SPRY) on behalf of investors that purchased or otherwise acquired ARS securities between March 9, 2026 and June 24, 2026 (the "Class Period").

The complaint alleges on June 24, 2026, after the market closed, ARS published a press release providing an update on payer access for neffy, which stated, in pertinent part, "[d]espite certain payer discussions ongoing until mid-June, based on recent feedback, no new commercial formulary additions or coverage decisions have been issued for neffy in the July 1, 2026 cycle." Following this news, the price of ARS stock fell $2.52 per share, or 23.9%, to close at $8.02 per share on June 25, 2026.